Mammoth Biosciences
Matan Drory Retwitzer has a diverse work experience in the field of data science and bioinformatics. Matan is currently working at Mammoth Biosciences as an Associate Director in Data Science. Prior to this, they held roles of Sr. Manager, Lead Data Scientist, and Computational Biologist at the same company.
Before joining Mammoth Biosciences, Matan worked as a self-employed Computational Biologist, providing consulting services.
Matan also has a strong academic background, having completed a PhD in computer science with a thesis in Bioinformatics at Ben Gurion University of the Negev. As part of their PhD, they worked on generating RNA sequences and testing them in vitro. Matan also completed a Master's thesis in Bioinformatics at the same university, where they developed algorithms for searching Ribo-switches on large DNA sequences.
Earlier in their career, Matan worked as an IMS Developer at Evogene, focusing on modeling and programming business processes. Matan also worked at GraphTech Computer Systems as an Engineering QE, and served as an Artillery Sergeant in the Israel Defense Forces.
Matan Drory Retwitzer holds a Doctor of Philosophy (PhD) degree in Computer Science from Ben-Gurion University of the Negev, which they obtained from 2015 to 2019. Prior to that, they completed their Master of Science (MSc) degree in Computer Science at the same university from 2013 to 2015. Matan also holds a Bachelor of Science (BSc) degree in computer science from Ben-Gurion University of the Negev, which they earned from 2009 to 2012. Matan graduated from Lod High School of Science in 2004 with a high school diploma Aleh, focusing on biology and computer science. In addition, Matan has obtained a certification as a Cloud Digital Leader from Google in October 2023.
This person is not in any teams
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.